GLP-1 Check — India's GLP-1 Information & Self-Assessment Tool
All Semaglutide Brands India
Generic SemaglutideObesity (Chronic Weight Management)
Sun Pharma logo

NoveltreatGeneric semaglutide for obesity (chronic weight management) in India 2026

by Sun Pharma · ₹750–2,000/month · DCGI approved December 2025

Active ingredient
Semaglutide (GLP-1 receptor agonist)
Indication
Obesity (Chronic Weight Management)
Manufacturer
Sun Pharmaceutical Industries Ltd
DCGI status
Approved December 2025
Price (MRP)
₹750–2,000/month
Format
Prefilled pen
Concealed needle, single-strength prefilled pen
Prescription
Schedule H — required

How Noveltreat compares

Noveltreat is Sun Pharma's obesity-indicated brand of generic semaglutide, approved by DCGI in December 2025 — the first Indian generic at the obesity dose. The concealed-needle prefilled pen reduces injection-related anxiety, a key adoption barrier for first-time semaglutide users.

About Sun Pharma

Sun Pharma is India's largest pharmaceutical company by revenue. Its semaglutide programme includes a Phase III clinical trial conducted in India, supporting an Indian-population safety and efficacy profile. Sun Pharma also markets Sematrinity, the type-2-diabetes indication of the same molecule.

Who is Noveltreat for?

Noveltreat is approved in India for chronic weight management in adults with obesity. Indian guideline eligibility typically requires BMI ≥27.5, or BMI ≥25 with weight-related comorbidities (T2D, PCOS, NAFLD, hypertension, dyslipidaemia, sleep apnea). Always confirmed by an endocrinologist or qualified physician.

Not sure if you qualify? Take the 5-minute Indian-guideline eligibility check →

Noveltreat for specific conditions

Noveltreat for PCOS →Noveltreat for fatty liver (NAFLD/MASLD) →Noveltreat for hypertension + obesity →Noveltreat for sleep apnea + obesity →

Noveltreat cost in India

MRP for Noveltreat: ₹750–2,000/month. Actual pharmacy pricing varies by city, pharmacy, and channel. Online prescription pharmacies typically offer modest discounts off MRP with cold-chain delivery; hospital pharmacy pricing is usually at MRP.

Compare with all India brands: GLP-1 therapy cost in India 2026 →

Compared to other GLP-1 brands in India

Noveltreat is an Indian generic semaglutide. Same active molecule as Ozempic and Wegovy (Novo Nordisk innovator brands), with clinical efficacy that follows the molecule rather than the brand. Other Indian generics include Sundae, Noveltreat, Obeda, Semaglyn, Sembolic, and Samakind — all at similar price points.

All GLP-1 comparisons →All Indian semaglutide brands →Clinical evidence library →GLP-1 blog (India) →

Noveltreat — frequently asked questions

Is Noveltreat available in India? Is it DCGI-approved?+
Yes — Noveltreat is DCGI-approved and currently available across India. The drug received DCGI approval in December 2025 for obesity / chronic weight management, manufactured by Sun Pharmaceutical Industries Ltd. It is distributed through licensed retail and online prescription pharmacies and hospital pharmacies across Indian metros and most tier-2 cities. Noveltreat is a Schedule H drug — a doctor's prescription is required. Take the GLP-1 Check 5-minute Indian-guideline assessment to see if you qualify.
What does Noveltreat cost in India in 2026?+
Noveltreat is priced at ₹750–2,000/month. Actual pharmacy pricing may vary by city and channel. For brand-by-brand price comparisons across all India brands, see our cost guide. Take the GLP-1 Check 5-minute Indian-guideline assessment to see if you qualify.
Do I need a prescription to buy Noveltreat?+
Yes — Noveltreat is a Schedule H drug in India and can only be dispensed against a valid prescription from a registered medical practitioner. Any legitimate online prescription pharmacy will require you to upload your prescription before order fulfillment.
Who is Noveltreat for?+
Noveltreat is approved for obesity / chronic weight management in India. Indian guideline eligibility typically requires BMI ≥27.5 (obesity indication) or HbA1c above target on first-line therapy (T2D indication), often with comorbidities at BMI ≥25. Take the GLP-1 Check 5-minute Indian-guideline assessment to see if you qualify.
How does Noveltreat compare to Ozempic and Wegovy?+
Noveltreat contains the same active molecule (semaglutide) as Ozempic and Wegovy. Clinical efficacy is comparable; the difference is brand, manufacturer support, pen design, and price. Noveltreat (₹750–2,000/month) is meaningfully cheaper than Ozempic (₹5,660+/month) or Wegovy (up to ₹16,400/month) — useful for cost-sensitive patients on long-term therapy.
Where can I buy Noveltreat in India?+
Noveltreat is a Schedule H drug — available through licensed retail and online prescription pharmacies and hospital pharmacies across India with a doctor's prescription. Always buy from a licensed pharmacy to avoid counterfeit products; never use sources that dispense without verifying a prescription. Take the GLP-1 Check 5-minute Indian-guideline assessment to see if you qualify.
Official

Manufacturer announcement

Sun Pharma — Semaglutide launch announcement (March 2026)

Additional source

Sun Pharma DCGI approval PR

GLP-1 Check is informational, not a medical diagnosis. Semaglutide is a Schedule H drug in India and requires a prescription from a registered medical practitioner. Always consult a qualified physician before starting any treatment.

Are you eligible for Noveltreat?

Take the free 5-minute triage to check your GLP-1 readiness against Indian clinical guidelines.

Check My Eligibility →

Looking at other brands?

See full price comparison across all 25+ DCGI-approved brands →